发明公开
- 专利标题： INTEGRIN RECEPTOR ANTAGONISTS
- 专利标题（中）： 整合受体拮抗剂
-
申请号： EP98963136.1申请日： 1998-12-14
-
公开(公告)号： EP1040098A1公开(公告)日： 2000-10-04
- 发明人: ASKEW, Ben, C. , COLEMAN, Paul, J. , DUGGAN, Mark, E. , HALCZENKO, Wasyl , HARTMAN, George, D. , HUNT, Cecilia , HUTCHINSON, John, H. , MEISSNER, Robert, S. , PATANE, Michael, A. , SMITH, Garry, R. , WANG, Jiabing
- 申请人： Merck & Co., Inc. (a New Jersey corp.)
- 申请人地址： 126 East Lincoln Avenue Rahway, N.J. 07065 US
- 专利权人： Merck & Co., Inc. (a New Jersey corp.)
- 当前专利权人： Merck & Co., Inc. (a New Jersey corp.)
- 当前专利权人地址： 126 East Lincoln Avenue Rahway, N.J. 07065 US
- 代理机构： Thompson, John Dr.
- 优先权： US69899P 19971217; GB9807382 19980406; US83209P 19980427; GB9811295 19980526; US92622P 19980713
- 国际公布： WO9931061 19990624
- 主分类号： C07D213/30
- IPC分类号： C07D213/30
摘要：
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αξβ3, αξβ5, and/or αξβ6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
公开/授权文献
- EP1040098B1 INTEGRIN RECEPTOR ANTAGONISTS 公开/授权日：2005-04-27
信息查询
